SymBio Pharmaceuticals Limited
SYMQY · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $9 | $10 | $26 | $11 |
| - Cash | $4 | $7 | $6 | $4 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $5 | $3 | $20 | $7 |
| Revenue | $2 | $6 | $10 | $8 |
| % Growth | -56.1% | -44.1% | 21.3% | – |
| Gross Profit | $2 | $4 | $8 | $6 |
| % Margin | 76.4% | 78.9% | 75.9% | 70.3% |
| EBITDA | -$4 | -$1 | $2 | $1 |
| % Margin | -154.1% | -12.8% | 20.6% | 13.4% |
| Net Income | -$4 | -$2 | $1 | $2 |
| % Margin | -156.3% | -35.1% | 11.8% | 24.6% |
| EPS Diluted | -84.06 | -49.19 | 29.77 | 52.32 |
| % Growth | -70.9% | -265.2% | -43.1% | – |
| Operating Cash Flow | -$3 | -$0 | $2 | $0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$3 | -$0 | $2 | $0 |